Cidara is using its proprietary Cloudbreak platform to develop drug-Fc conjugates (DFCs) that couple targeted small molecules and peptides to a human antibody fragment (Fc). These “single molecule cocktails” are designed to inhibit specific disease targets while simultaneously engaging the immune system.
Cidara’s Cloudbreak platform is a fundamentally new approach to treating and preventing serious diseases such as solid tumor cancers and viral infections. By applying the principles of immuno-oncology, Cidara is creating novel drugs that stably couple targeted small molecules or peptides, to a proprietary variant of a human antibody fragment (Fc). Structurally, these molecules are engineered to combine the best attributes of small molecules and antibodies and overcome the limitations of each. These immunotherapeutic agents are designed to directly inhibit disease targets while simultaneously directing immune-mediated clearance of disease. The two distinct and complementary mechanisms are designed to provide potency and selectivity, while also providing an extended half-life and attracting an immune response to maximize disease eradicating activity.
Cidara’s most advanced DFC development candidate, CD388, is being studied in a Phase 2 clinical trials in partnership with Janssen for prevention of seasonal influenza A and B.
Cidara is advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases.